Insights into the Clinico-Epidemiological Aspects of Non-Epithelial Ovarian Tumor Emphasizing Diagnosis and Tailored Surgical Approach; a Single Institutional Retrospective Study

Abdelrahman, Ahmad A; Eldmaty, Asmaa M.; Elshahat, Ahmed; Min Hsia, Shih; Abdellatif, Rasha Mohamed

doi:10.21608/jcbr.2024.265911.1337

Insights into the Clinico-Epidemiological Aspects of Non-Epithelial Ovarian Tumor Emphasizing Diagnosis and Tailored Surgical Approach; a Single Institutional Retrospective Study

Document Type : Original Article

Authors

¹ Clinical oncology department, Faculty of medicine ,Mansoura University, Egypt

² Clinical oncology department, faculty of medicine, Mansoura University, Egypt

³ Clinical oncology department, Faculty of medicine , Mansoura University, Egypt

⁴ TMU Research Center for digestive medicine, Taipei Medical University, Taipei, Taiwan

⁵ Clinical oncology department, Faculty of medicine, Mansoura University, Egypt

10.21608/jcbr.2024.265911.1337

Abstract

Background: Ovarian cancers account for approximately 27% of all female tumors, with non-epithelial ovarian cell carcinoma being rare at around 10% of overall ovarian cancer cases. The aim of this study is to recognize the prognostic factors Reporting survival outcome in the form of OAS, DFS, and PFS.

Aim and Objective(s):Defining the lines of treatment have been uses and recognize the prognostic factors Reporting survival outcome OAS, PFS, and DFS.

Patients and Methods: This study included 56 patients, were recruited in the period between January 2005 and December 2020 with the following criteria: Proven non-epithelial ovarian carcinoma, all stages, age greater than 18 years.

Results: all 56 patients (100%) underwent surgery: 96.4% had upfront early debulking, and 3.6% had interval debulking post-neoadjuvant chemotherapy. Fertility Sparing Surgery was performed in 50%, optimal debulking in 41.4%. Surgical debulking left no residual disease in 78.6%; 12 patients had residual disease.Chemotherapy was administered to 55.4% of patients, with 67.7% receiving the BEP regimen and 9 patients receiving other regimens. Pathological responses in 12 patients with residual disease 75% achieved complete response. The median (OAS) was 66 months. The 5-year OAS rate was 94.6% for 53 patients. Median (PFS) was 66 months, with a 5-year PFS rate of 85.7% for 48 patients. Among 44 completely treated patients, (DFS) was 83 months, with a 5-year DFS rate of 93.2% for 41 patients.

Conclusion: by univariate analysis; performance status, stage, type of surgery, and tumor residual after debulking surgery were significant prognostic factors for survival.

Keywords